Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: A randomized comparison of stem cell transplantation with drug treatment

Leukemia

Volumn 30, Issue 3, 2016, Pages 562-569

  Gratwohl, A ^a   Pfirrmann, M ^b   Zander, A ^c   Kroger N ^c   Beelen, D ^d   Novotny, J ^d   Nerl, C ^e   Scheid, C ^f   Spiekermann, K ^g   Mayer, J ^h   Sayer, H G ⁱ   Falge, C ^j   Bunjes, D ^k   Dohner H ^k   Ganser, A ^l   Schmidt Wolf, I ^m   Schwerdtfeger, R ⁿ   Baurmann, H ⁿ   Kuse, R ^o   Schmitz, N ^o   Wehmeier, A ^p   Fischer, J T ^q   Ho, A D ^r   Wilhelm, M ^j,s   Goebeler, M E ^s   Lindemann, H W ^t   Bormann, M ^u   Hertenstein, B ^u   Schlimok, G ^v   Baerlocher, G M ^w   Aul, C ^x   Pfreundschuh, M ^y   Fabian, M ^z   Staib, P ^aa   Edinger, M ^ab   Schatz, M ^ac   Fauser, A ^ad   Arnold, R ^ae   Kindler, T ^af   Wulf, G ^ag   Rosselet, A ^ah   Hellmann, A ^ai   Schafer E ^aj   Prummer O ^ak   Schenk, M ^al   Hasford, J ^b   Heimpel, H ^k   Hossfeld, D K ^c   Kolb, H J ^g   Busche G ^l   Haferlach, C ^am   Schnittger, S ^am   Muller M C ^an   Reiter, A ^an   Berger, U ^an   Saussele S ^an   Hochhaus, A ^i,an   Hehlmann, R ^an   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e Klinikum Schwabing   (Germany)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h UNIVERSITY HOSPITAL BRNO   (Czech Republic)

ⁱ JENA UNIVERSITY HOSPITAL   (Germany)

^j KLINIKUM NÜRNBERG   (Germany)

^k UNIVERSITY HOSPITAL ULM   (Germany)

^l HANNOVER MEDICAL SCHOOL   (Germany)

^m UNIVERSITY HOSPITAL BONN   (Germany)

ⁿ DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^o DEPARTMENT OF CARDIOLOGY   (Germany)

^p UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^q STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^r UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^s UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^t St Marien Hospital   (Germany)

^u KLINIKUM BREMEN MITTE   (Germany)

^v KLINIKUM AUGSBURG   (Germany)

^w UNIVERSITY OF BERN   (Switzerland)

^x Institute of Radiology   (Germany)

^y SAARLAND UNIVERSITY   (Germany)

^z Klinikum Stuttgart Burgerhospital   (Germany)

^aa ST ANTONIUS HOSPITAL ESCHWEILER   (Germany)

^ab UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^ac St Vincentius Kliniken   (Germany)

^ad Klinik fur Knochenmarktransplantation und Hamatologie/Onkologie GmbH   (Germany)

^ae CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^af UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^ag UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^ah LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^ai MEDICAL UNIVERSITY OF GDANSK   (Poland)

^aj Onkologische Schwerpunktpraxis   (Germany)

^ak Klinikum Kempten Oberallgau   (Germany)

^al KRANKENHAUS BARMHERZIGE BRÜDER   (Germany)

^am MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^an UNIVERSITY OF MANNHEIM   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; INTERFERON; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL CRISIS; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG SUBSTITUTION; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKEMIA REMISSION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; AGED; ALLOTRANSPLANTATION; CLINICAL TRIAL; COMPARATIVE STUDY; DONOR; FAMILY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; REMISSION; RISK; SURVIVAL ANALYSIS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FAMILY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; REMISSION INDUCTION; RISK; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84959355599     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.281     Document Type: Article

References (31)

1. Apperley JF. Chronic myeloid leukaemia. Lancet 2015; 385: 1447-1459
2. Hehlmann R A chance of cure for every patient with chronic myeloid leukemia?. N Engl J Med 1998; 338: 980-982
3. O'Brien S, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004
4. Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave PB, et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1984; 1: 665-668
5. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813-1826
6. Fefer A, Einstein AB, Thomas ED, Buckner CD, Clift RA, Glucksberg H, et al. Bone-marrow transplantation for hematologic neoplasia in 16 patients with identical twins. N Engl J Med 1974; 290: 1389-1393
7. Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant 2015; 50: 476-482
8. Gratwohl A, Baldomero H, Gratwohl M, Aljurf M, Bouzas LF, Horowitz M, et al. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica 2013; 98: 1282-1290
9. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872-884
10. National Cancer Institute at the National Institutes of Health. Treatment options for chronic-phase CML. High-dose therapy followed by allogeneic BMT or SCT. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/CML/HealthPro fessional/Page4#Section-271 (last assessed 21 February 2015
11. Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, et al. Long-Term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010; 116: 3758-3765
12. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007; 109: 4686-4692
13. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091-2101
14. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087-1092
15. Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J, et al. Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol 2011; 29: 1980-1986
16. Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115: 1880-1885
17. Oyekunle A, Zander AR, Binder M, Ayuk F, Zabelina T, Christopeit M, et al. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol 2013; 92: 487-496
18. Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H, et al. Interferon-Alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 1999; 94: 3668-3677
19. CML Autograft Trials Collaboration. Autologous stem cell transplantation in chronic myeloid leukaemia: a meta-Analysis of six randomized trials. Cancer Treat Rev 2007; 33: 39-47
20. Lauseker M, Hasford J, Pfirrmann M, Hehlmann R, German CMLSG. The impact of health care settings on survival time of patients with chronic myeloid leukemia. Blood 2014; 123: 2494-2496
21. Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M, et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 2012; 119: 4083-4090
22. Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011; 118: 1208-1215
23. Pfirrmann M, Saussele S, Hochhaus A, Reiter A, Berger U, Hossfeld DK, et al. Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia. J Cancer Res Clin Oncol 2014; 140: 1367-1381
24. Simon R, Makuch RW A non-parametric graphical representation of the relationship between survival and the occurence of an event: application to responder versus non-responder bias. StatMed 1984; 3: 35-44
25. Mantel N, Byar DP. Evaluation of response-Time data involving transient states: an illustration using heart-Transplant data. J Am Stat Assoc 1974; 69: 81-86
26. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850-858
27. Innes AJ, Apperley JF. Chronic myeloid leukemia-Transplantation in the tyrosine kinase era. Hematol Oncol Clin N Am 2014; 28: 1037-1053
28. Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014; 32: 415-423
29. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 2014; 371: 339-348
30. Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, et al. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. Health Technol Assess (Winchester, England) 2012; 16, iii-iv, 1-277
31. Mo XD, Jiang Q, Xu LP, Liu DH, Liu KY, Jiang B, et al. Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib. Bone Marrow Transplant 2014; 49: 576-580